In NSCLC cell line (A549) with KRAS G12S mutation, the combination of mitogen-activated protein kinase (MEK) inhibitor trimetinib and IK-930 exerted a synergistic anti-tumor effect. This evidence concerns the gene MAP2K7 and neoplasm.